BR112015021692A2 - formulação de dosagem oral sólida de inibidor de hcv no estado amorfo - Google Patents

formulação de dosagem oral sólida de inibidor de hcv no estado amorfo

Info

Publication number
BR112015021692A2
BR112015021692A2 BR112015021692A BR112015021692A BR112015021692A2 BR 112015021692 A2 BR112015021692 A2 BR 112015021692A2 BR 112015021692 A BR112015021692 A BR 112015021692A BR 112015021692 A BR112015021692 A BR 112015021692A BR 112015021692 A2 BR112015021692 A2 BR 112015021692A2
Authority
BR
Brazil
Prior art keywords
solid oral
amorphous state
dosage forms
oral dosage
compound
Prior art date
Application number
BR112015021692A
Other languages
English (en)
Inventor
Telang Chitra
Zhong Li
Wang Zeren
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR112015021692A2 publication Critical patent/BR112015021692A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Abstract

resumo patente de invenção: "formulação de dosagem oral sólida de inibidor de hcv no estado amorfo". a presente invenção descreve aqui formas de dosagem oral sólidas contendo composto (1) ou um sal do mesmo farmaceuticamente aceitável: em que o composto (1) está no estado amorfo. também descritos estão formas de dosagem oral sólida compreendendo uma composição do composto (1) no estado amorfo, e um ou mais excipientes farmaceuticamente aceitáveis. o composto (1) é um inibidor específico do vírus de hepatite c (hcv) ns3/4a protease serina. desse modo, também estão descritos aqui métodos para usar as formas de dosagem sólida descritas no tratamento de infecção por hcv. também estão descritos processos para a preparação de formas de dosagem oral sólida.
BR112015021692A 2013-03-15 2014-03-13 formulação de dosagem oral sólida de inibidor de hcv no estado amorfo BR112015021692A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791093P 2013-03-15 2013-03-15
PCT/US2014/026028 WO2014151575A1 (en) 2013-03-15 2014-03-13 Solid oral dosage formulation of hcv inhibitor in the amorphous state

Publications (1)

Publication Number Publication Date
BR112015021692A2 true BR112015021692A2 (pt) 2017-07-18

Family

ID=50771327

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015021692A BR112015021692A2 (pt) 2013-03-15 2014-03-13 formulação de dosagem oral sólida de inibidor de hcv no estado amorfo

Country Status (16)

Country Link
US (1) US9732076B2 (pt)
EP (1) EP2968154B1 (pt)
JP (1) JP6130585B2 (pt)
KR (1) KR20150129005A (pt)
CN (1) CN105228593B (pt)
AU (1) AU2014233705C1 (pt)
BR (1) BR112015021692A2 (pt)
CA (1) CA2903831A1 (pt)
CL (1) CL2015002681A1 (pt)
EA (1) EA032322B1 (pt)
IL (1) IL240840A0 (pt)
MX (1) MX364431B (pt)
PH (1) PH12015502258B1 (pt)
SA (1) SA515361071B1 (pt)
UA (1) UA116237C2 (pt)
WO (1) WO2014151575A1 (pt)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004099442A (ja) * 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
PT1654261E (pt) * 2003-05-21 2008-01-18 Boehringer Ingelheim Int Compostos inibidores da hepatite c
BRPI0511900A (pt) 2004-06-08 2008-01-22 Vertex Pharma composições farmacêuticas
AU2007226983A1 (en) 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
CA2699335A1 (en) 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg. Solid dispersion product containing n-aryl urea-based compound
PE20110388A1 (es) * 2008-09-16 2011-07-01 Boehringer Ingelheim Int Formas cristalinas de un derivado de peptido como inhibidores de hcv
SG2014008981A (en) * 2009-02-27 2014-04-28 Ortho Mcneil Janssen Pharm Amorphous salt of a macrocyclic inhibitor of hcv
CA2767692C (en) * 2009-07-07 2017-03-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition for a hepatitis c viral protease inhibitor
NZ605440A (en) * 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
EP2797586A1 (en) * 2011-12-29 2014-11-05 AbbVie Inc. Solid compositions comprising an hcv inhibitor

Also Published As

Publication number Publication date
KR20150129005A (ko) 2015-11-18
PH12015502258A1 (en) 2016-02-01
IL240840A0 (en) 2015-10-29
UA116237C2 (uk) 2018-02-26
WO2014151575A1 (en) 2014-09-25
EA201500932A1 (ru) 2016-03-31
CN105228593A (zh) 2016-01-06
JP2016514156A (ja) 2016-05-19
EP2968154B1 (en) 2020-06-17
CL2015002681A1 (es) 2016-04-08
MX2015012936A (es) 2015-12-03
SA515361071B1 (ar) 2017-11-29
PH12015502258B1 (en) 2016-02-01
CA2903831A1 (en) 2014-09-25
EA032322B1 (ru) 2019-05-31
US9732076B2 (en) 2017-08-15
AU2014233705C1 (en) 2019-10-10
MX364431B (es) 2019-04-26
JP6130585B2 (ja) 2017-05-17
EP2968154A1 (en) 2016-01-20
CN105228593B (zh) 2018-08-28
US20160185767A1 (en) 2016-06-30
AU2014233705B2 (en) 2019-01-03
AU2014233705A1 (en) 2015-09-10

Similar Documents

Publication Publication Date Title
PH12018550201A1 (en) Hepatitis b antiviral agents
UY37998A (es) Agentes antivirales contra la hepatitis b
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
BR112015025766A2 (pt) derivado de nucleosídeo altamente ativo para o tratamento de hcv
CL2008001005A1 (es) Compuestos derivados de azufre, inhibidores de la serina proteasa ns3 del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos asociados a la proteasa de hcv.
EA200970805A1 (ru) Ингибиторы серинпротеаз для лечения hcv инфекций
BR112012024661A2 (pt) composto, composição farmacêutica e método de tratamento de um hospedeiro infectado com vírus de hepatite c
BR112013020042A2 (pt) inibidores de vírus da hepatite c
BRPI0612104A8 (pt) composto, mistura diastereomérica, composição farmacêutica, e, método para tratar infecções por hepatite c em um paciente e para tratar infecções por hcv em um paciente
BR112012014729A2 (pt) terapia combinada contra hcv
RU2015114543A (ru) Способы лечения гепатита с
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي
BR112014019897A8 (pt) Espiro[2.4]heptanos para tratamento de infecções por flaviviridae
BR112014013972A8 (pt) inibidores de hcv nssa
CO7131387A2 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
EA201170605A1 (ru) Циклоундекадепсипептидные соединения и применение указанных соединений в качестве лекарственного средства
WO2015160907A3 (en) Potent and selective inhibitors of hepatitis c virus
BR112014015582A8 (pt) compostos antivirais
RU2015114566A (ru) Способы лечения гепатита с
EA201692514A1 (ru) Фармацевтические композиции на основе софосбувира и рибавирина с модифицированным высвобождением
EA201300422A1 (ru) Твердофазные формы активного ингибитора hcv
BR112015021692A2 (pt) formulação de dosagem oral sólida de inibidor de hcv no estado amorfo
MX2014014878A (es) Combinacion de agentes terapueticos para tratar infeccion por el virus de la hepatitis c (hcv).
MX2016016119A (es) Compuestos quimicos y composiciones farmaceuticas que inhiben el virus de la hepatitis c y sus aplicaciones.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements